Clinical Trials | March 24, 2026
Pfizer and Valneva report promising Phase 3 Lyme disease vaccine results
The company plans to submit the vaccine for regulatory review
The company plans to submit the vaccine for regulatory review
Zydus has developed an innovative formulation of Semaglutide Injection in a prefilled cartridge administered using a reusable patient-friendly pen device
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The company announced positive topline data from the Phase 3 ADorable-1 trial
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
Giredestrant shows promise despite missing primary goal
Germany will be the first launch market
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
Subscribe To Our Newsletter & Stay Updated
